25 May 2013
Keywords: boeh, ingel, enters, 265m, nanobody, deal, belgian
Article | 15 January 2007
Belgian biotechnology firm Ablynx NV has signed a deal worth over $265.0 million to allow privately-held German drug major Boehringer Ingelheim
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 January 2007
24 May 2013
© 2013 thepharmaletter.com